(Source: MARKETWIRE)
Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops,
manufactures, markets and licenses point of care diagnostic tests,
announced today that the Company will release financial results for
the third quarter of 2009, following the close of the market on
Wednesday, November 4, 2009. The Company's 10-Q and earnings press
release will be available immediately after 4:00 p.m. on our web site
on page:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=121584&eventID=2517574
Lawrence A. Siebert, Chembio's president and chief executive officer,
will host an investment community conference call beginning at 4:15
p.m. Eastern Time on Wednesday, November 4, 2009, to discuss these
results and to answer questions. He will be joined by Richard Larkin,
Chembio's chief financial officer.
To participate on the conference call, please dial (877) 407-8031
from the U.S. or (201) 689-8031 from outside the U.S. In addition,
following the completion of the call, a telephone replay will be
accessible until November 11, 2009 at 11:59 p.m. Eastern Time by
dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside
the U.S. and entering reservation account number 286 and conference
ID #: 336231. The conference call may also be accessed via the
internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=151441.
An archive of the webcast will be available for 90 days on the
Company's website at www.chembio.com.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investor Center section of
Chembio's website at www.chembio.com. To listen to the live call,
please go to the website 15 minutes prior to its start to register,
download, and install the necessary audio software. A replay will be
available on the website for a limited time.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and
markets proprietary rapid diagnostic tests in the growing $5 billion
point-of-care testing market. Chembio's two FDA PMA-approved,
CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness
Medical Innovations, Inc. Chembio markets its HIV STAT-PAK(R) line of
rapid HIV tests internationally to government and donor-funded
programs directly and through distributors. Chembio has developed a
patented point-of-care test platform technology, the Dual Path
Platform (DPP(R)) technology, which has significant advantages over
lateral-flow technologies. This technology is providing Chembio with
a significant pipeline of business opportunities for the development
and manufacture of new products based on DPP(R). Headquartered in
Medford, NY, with approximately 100 employees, Chembio is licensed by
the U.S.
